Bispecific Antibody Goes to HybridAifen Li1,2, Li Li1,2, Qing Li1,2 and Zhong Wang1,2*
- *Corresponding Author:
- Zhong Wang
Center for Cellular and Structural Biology
Sun Y at-Sen University
Received date: July 19, 2016; Accepted date: August 18, 2016; Published date: August 23, 2016
Citation: Li A, Li L, Li Q, Wang Z (2016) Bispecific Antibody Goes to Hybrid. Immunother Open Acc 2:123. doi: 10.4172/2471-9552.1000123
Copyright: © 2016 Li A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Bispecific antibody has being actively pursued in cancer immunotherapy. By binding to specific surface proteins on T cells or NK cells, bispecific antibodies recruit T cells or NK cells to close proximity of tumor cells and kill tumor cells. A number of bispecific antibodies with diverse formats have been developed and some of them already in clinical stages. In the study of “Her2-S-Fab bispecific antibody has potent cytotoxicity against Her2-expressing tumor cells”, a novel format of bispecific antibody was reported. Here we briefly describe this study and its implications in cancer immunotherapy.